2022 Drug Safety Communications

Current Drug Safety Communications More Drug Safety Communications

• 6-30-2022: FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)
• 6-1-2022: FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns
• 3-30-2022: FDA recommends thyroid monitoring in babies and young children who receive injections of iodine-containing contrast media for medical imaging
• 2-3-2022: FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)
• 1-12-2022: FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain